% | $
Quotes you view appear here for quick access.

Dendreon Anonim Ortaklik Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • bullcoach_1 bullcoach_1 Jan 10, 2013 10:46 AM Flag

    No sellers at all down here:

    Why? Has Huge potential, in P3

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • AF said it they will have to raise additional capital which will put a cap on the stock for a while. I believe in the end they will get denied by the FDA and even if they get approval, HGSI's lupus drug was a flop. Not worth the risk to me. Much better opps out there.

      "Anthera shares are down 90%, making it the worst performing biopharma stock in 2012. A phase III study of Anthera's cardiovascular disease drug varespladib was halted for futility in March. In June, the company's lupus drug blisibimod came up lame in a phase II study. While Blisibimod demonstrated some positive response trends among certain lupus patients, the mid-stage study overall was a failure.

      The few supporters Anthera has left believe blisibimod could be as effective, perhaps more so, than Benlysta, the lupus drug developed by Human Genome Sciences and later acquired by GlaxoSmithKline. Unfortunately, Benlysta is a mediocre lupus drug and a commercial flop. At $3 billion, Glaxo way overpaid for Human Genome."

0.130.00(0.00%)Nov 18 4:00 PMEST